RVTY Revvity Corp: Multiplikator forward rega marang pendapatan
The growth of Revvity, Inc. (RVTY) shares depends on the recovery of biotech demand and a focus on high-margin consumables. The forward P/S ratio, which currently stands at 2.30, serves as an indicator of stability. High barriers to entry in a consolidated industry and the company's pricing power, which allows it to index the cost of proprietary reagents that laboratories rely on, mitigate the risks.
Rincian analitis perusahaan Revvity Corp (RVTY)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- rincian valuasi buku bisnis:
- rincian struktur utang lan likuiditas bisnis:
Rasio Total Utang marang Ekuitas Revvity, Inc.|RVTY - Rasio silihan jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Revvity, Inc.|RVTY - Utang kumulatif perusahaan|Utang marang nilai buku Revvity Corp|RVTY - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Revvity|Likuiditas cepet revvity.com
- indikator pendapatan resik lan kelipatan nilai:
RVTY - Bathi perusahaan|Proyeksi bathi mangsa ngarep Revvity, Inc.|RVTY - Koefisien rega marang bathi|Prakiraan rega marang bathi PerkinElmer|RVTY - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Revvity Corp|RVTY - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Revvity|RVTY - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan revvity.com|RVTY - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Revvity, Inc.
- indikator pendapatan dodolan lan penghasilan bisnis:
Analisis wiwitan perusahaan:Revvity (RVTY)
The integration of ESG standards and the greening of Revvity, Inc. (RVTY) production facilities enhance the long-term attractiveness of the business for institutional investors. The projected price-to-sales ratio measures the market premium for the scalability of this model, assessing future sales relative to current capitalization. This chart moving beyond historical norms signals an asset overvaluation, which could lead to an unjustified increase in the cost of capital.
Pesaing wigati
Multiplikator Forward P/S A (Agilent)|Quest Diagnostics Inc. (DGX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ILMN: Multiplikator forward rega marang pendapatan|EXAS: Rasio rega marang prakiraan pendapatan|BIO (Bio-Rad Laboratories) - Multiplikator forward rega marang pendapatan|NNNN (anbio.com) - Rasio rega marang prakiraan pendapatan|SHC (Sotera Health) - Multiplikator Forward P/S|Quidel Corporation (QDEL) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan OPK (OPKO Corp)|Rasio rega marang pendapatan sing dikarepake CDNA|Maravai LifeSciences - Multiplikator forward rega marang pendapatan|fulgentgenetics.com (FLGT) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|LAB: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan CTKB (Cytek Biosciences Inc)|OSUR: Multiplikator Forward P/S|XGN - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan MDxHealth SA|Kapitalisasi marang prakiraan pendapatan LUCD (luciddx.com)|Multiplikator Forward P/S PRE|Multiplikator forward rega marang pendapatan imdxinc.com IMDX|Trinity Biotech - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake ProPhase Labs Corp (PRPH)|AIMD - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan CODX (codiagnostics.com)|HSCS (HeartSciences) - Multiplikator forward rega marang pendapatan|BMRA (Biomerica Inc.) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan CDIO|ONCO (Onconetix Corporation) - Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan VRAX (Virax Biolabs Group)|BJDX - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Aspira Women's Health Inc. AWH|AXDX - Multiplikator forward rega marang pendapatan|centogene.com - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Enzo Biochem, Inc.|FRES: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan GENE|ME (23andMe) - Multiplikator Forward P/S|Multiplikator Forward P/S Psychemedics Corp.
